Nautilus Biotechnology, Inc. (NAUT)
NASDAQ: NAUT · Real-Time Price · USD
2.330
+0.040 (1.75%)
At close: Mar 13, 2026, 4:00 PM EDT
2.410
+0.080 (3.43%)
After-hours: Mar 13, 2026, 6:47 PM EDT
Nautilus Biotechnology Employees
Nautilus Biotechnology had 130 employees as of December 31, 2025. The number of employees decreased by 25 or -16.13% compared to the previous year.
Employees
130
Change
-25
Growth
-16.13%
Revenue / Employee
n/a
Profits / Employee
-$453,854
Market Cap
294.29M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 130 | -25 | -16.13% |
| Sep 30, 2025 | 124 | -37 | -22.98% |
| Jun 30, 2025 | 128 | -36 | -21.95% |
| Mar 31, 2025 | 134 | -29 | -17.79% |
| Dec 31, 2024 | 155 | -12 | -7.19% |
| Sep 30, 2024 | 161 | 1 | 0.63% |
| Jun 30, 2024 | 164 | 11 | 7.19% |
| Mar 31, 2024 | 163 | 10 | 6.54% |
| Dec 31, 2023 | 167 | 33 | 24.63% |
| Sep 30, 2023 | 160 | 33 | 25.98% |
| Jun 30, 2023 | 153 | 29 | 23.39% |
| Mar 31, 2023 | 153 | 34 | 28.57% |
| Dec 31, 2022 | 134 | 21 | 18.58% |
| Sep 30, 2022 | 127 | 30 | 30.93% |
| Jun 30, 2022 | 124 | 35 | 39.33% |
| Mar 31, 2022 | 119 | 30 | 33.71% |
| Dec 31, 2021 | 113 | 56 | 98.25% |
| Sep 30, 2021 | 97 | 40 | 70.18% |
| Jun 30, 2021 | 89 | - | - |
| Mar 31, 2021 | 89 | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Puma Biotechnology | 179 |
| AC Immune | 172 |
| Cabaletta Bio | 151 |
| Prelude Therapeutics | 131 |
| C4 Therapeutics | 110 |
| Protara Therapeutics | 33 |
| Avalo Therapeutics | 23 |
| XOMA Royalty | 13 |
NAUT News
- 7 days ago - Nautilus Biotechnology, Inc. (NAUT) Presents at TD Cowen 46th Annual Health Care Conference Transcript - Seeking Alpha
- 15 days ago - Nautilus Biotechnology, Inc. (NAUT) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 22 days ago - Nautilus Biotechnology to Participate in the TD Cowen 46th Annual Health Care Conference - GlobeNewsWire
- 4 months ago - Nautilus Biotechnology Reports Successful Installation and Testing of its First Field Evaluation Unit at the Buck Institute for Research on Aging - GlobeNewsWire
- 4 months ago - Nautilus Biotechnology, Inc. (NAUT) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 6 months ago - Nautilus Biotechnology, Inc. (NAUT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 7 months ago - Nautilus Biotechnology to Participate in Upcoming September Investor Conferences - GlobeNewsWire
- 8 months ago - Nautilus Biotechnology, Inc. (NAUT) Q2 2025 Earnings Conference Call Transcript - Seeking Alpha